INGELHEIM, Germany and BASEL, Switzerland I 5, 2024 I Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

INGELHEIM, Germany I 16, 2024 I Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the ...

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D ...

Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded ...

There have been tens of thousands of lawsuits since 2020 and there are no doubt many more in the pipeline but few have gone to trial ... unable to decide whether German pharmaceutical Boehringer ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, ...